CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Growing cancer research
4.1.2. Increasing demand for monoclonal bodies
4.1.3. Rapid growth in biotechnology and biopharmaceutical industries
4.1.4. Rising healthcare expenditure
4.1.5. Growing number of collaborations, partnerships, and acquisitions
4.2. Market Restraints & Challenges
4.2.1. The high cost of advanced primary cells
4.2.2. Risk of contamination
4.3. Market Opportunities
4.3.1. Advanced biomedical research using primary cells in 3D culture
CHAPTER 5. GLOBAL PRIMARY CELLS MARKET – BY ORIGIN
5.1. Skin Cells
5.2. Gastrointestinal Cells
5.3. Liver Cells
5.4. Lung Cells
5.5. Renal Cells
5.6. Heart
5.7. Hematopoietic Cells
5.8. Skeletal and Muscle Cells
5.9. Others
CHAPTER 6. GLOBAL PRIMARY CELLS MARKET – BY TYPE
6.1. Human Primary Cells
6.2. Animal Primary Cells
CHAPTER 7. GLOBAL PRIMARY CELLS MARKET – BY END USER
7.1. Research Centers
7.2. Life Science Research Companies
CHAPTER 8. GLOBAL PRIMARY CELLS MARKET - BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. U.S.
8.2.2. Canada
8.2.3. Mexico
8.2.4. Costa Rica
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Chile
8.3.4. Columbia
8.3.5. Others
8.4. Europe
8.4.1. U.K.
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Spain
8.4.6. Russia
8.4.7. Netherlands
8.4.8. Switzerland
8.4.9. Poland
8.4.10. Others
8.5. APAC
8.5.1. China
8.5.2. Japan
8.5.3. India
8.5.4. South Korea
8.5.5. Australia & New Zealand
8.5.6. Malaysia
8.5.7. Singapore
8.5.8. Others
8.6. Middle East & Africa
8.6.1. UAE
8.6.2. Saudi Arabia
8.6.3. Iran
8.6.4. Iraq
8.6.5. Qatar
8.6.6. South Africa
8.6.7. Algeria
8.6.8. Morocco
8.6.9. Nigeria
8.6.10. Egypt
8.6.11. Others
CHAPTER 9. GLOBAL PRIMARY CELLS MARKET - COMPANY PROFILES
9.1. Lonza Group
9.2. Thermo Fisher Scientific
9.3. Merck KGaA
9.4. Cell Biologics
9.5. Promocell
9.6. ZenBio, Inc.
9.7. AllCells, LLC.
9.8. STEMCELL Technologies Inc.
9.9. American Type Culture Collection
9.10. Axol Biosciences
9.11. Advanced Cell & Gene Therapy, LLC
9.12. Advanced Vision Therapies, Inc.
9.13. Altogen Biosystems
9.14. Cellerant Therapeutics Inc.
9.15. Arthrogen
CHAPTER 10. GLOBAL PRIMARY CELLS MARKET - COMPETITIVE
LANDSCAPE
10.1. Market Share Analysis
10.2. Strategies adopted by top companies
10.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 11. MARKET INSIGHTS
11.1. Industry Experts Insights
11.2. Analysts Opinions
11.3. Investment Opportunities
CHAPTER 12. APPENDIX
12.1. List of Tables
12.2. List of Figures
